Curis (CRIS) Return on Capital Employed (2011 - 2026)
Curis (CRIS) reported Return on Capital Employed of 71.81% for Q1 2026, up 13747.0% on a YoY basis from N/an in Q1 2025, and down 22.28% quarter-over-quarter from 58.73% in Q4 2025.
Curis (CRIS) Return on Capital Employed (2011 - 2026) Analysis & Trends
Curis has reported Return on Capital Employed for 16 years, with the latest figure at 71.81% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 13747.0% year-over-year to 71.81%; the trailing twelve-month figure through Mar 2026 stood at 71.81% (up 13747.0% YoY), and the FY2025 full-year result was 34.54%, up 7613.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 71.81%, down from 58.73% in the prior quarter.
- The five-year high for Return on Capital Employed was 34.12% in Q1 2022, with the low at 402.63% in Q3 2025.
- Historically, Return on Capital Employed has averaged 119.77% across 5 years, with a median of 71.81% in 2026.
- Annual changes were most pronounced in 2025 — Return on Capital Employed slumped 20702 bps — and 2026, when it soared 13747 bps.
- Curis' Return on Capital Employed stood at 50.1% in 2022, then slumped by 57 bps to 78.45% in 2023, then tumbled by 149 bps to 195.0% in 2024, then surged by 70 bps to 58.73% in 2025, then slipped by 22 bps to 71.81% in 2026.
- The last three Return on Capital Employed figures came in at 71.81% (Q1 2026), 58.73% (Q4 2025), and 402.63% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -107.40% |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -50.43% |
| 10 | Curis | 8.58 Mn | -6.42 Mn | - | -71.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -71.81% |
| Dec 31, 2025 | -58.73% |
| Sep 30, 2025 | -402.63% |
| Jun 30, 2025 | -254.69% |
| Mar 31, 2025 | -209.28% |
| Dec 31, 2024 | -195.00% |
| Sep 30, 2024 | -195.61% |
| Jun 30, 2024 | -134.45% |
| Mar 31, 2024 | -84.27% |
| Dec 31, 2023 | -78.45% |
| Sep 30, 2023 | -63.12% |
| Jun 30, 2023 | -58.43% |
| Mar 31, 2023 | -52.88% |
| Dec 31, 2022 | -50.10% |
| Sep 30, 2022 | -49.39% |
| Jun 30, 2022 | -43.06% |
| Mar 31, 2022 | -34.12% |
| Dec 31, 2021 | -27.36% |
| Sep 30, 2021 | -21.40% |
| Jun 30, 2021 | -17.10% |